Proteomic applications for differential diagnosis of histologically identical tumors

Neurology

Volumn 61, Issue 11, 2003, Pages 1626-1627

  Vortmeyer, Alexander O ^a   Weil, Robert J ^a   Zhuang, Zhengping ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; SOLID TUMOR; VON HIPPEL LINDAU DISEASE;

EID: 0344306381     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000096168.85260.60     Document Type: Article

References (7)

1. Weider N, ed. The difficult diagnosis in surgical pathology. Philadelphia: Saunders, 1996.
2. Maher ER, Kaelin WG Jr. von Hippel-Lindau disease. Medicine 1997;76:381-391.
3. Bohling T, Plate KH, Haltia MJ, Alitalo K, Neumann HPH. Von Hippel-Lindau disease and capillary hemagioblastoma. In: Kleihues P, Cavenee WH, eds. Pathology and genetics of tumors of the central nervous system. Lyon: IARC Press, 2000:223-226.
4. Bret P, Streichenberger N, Guyotat J. Metastasis of renal carcinoma to a cerebellar hemangioblastoma in a patient with von Hippel Lindau disease: a case report. Br J Neurosurg 1999;13:413-416.
5. Hamazaki S, Nakashima H, Matsumoto K, Taguchi K, Okada S. Metastasis of renal cell carcinoma to central nervous system hemangioblastoma in two patients with von Hippel-Lindau disease. Pathol Int 2001;51:948-953.
6. Frank TS, Trojanowski JQ, Roberts SA, Brooks JJ. A detailed immunohistochemical analysis of cerebellar hemangioblastoma: an undifferentiated mesenchymal tumor. Mod Pathol 1989;2:638-651.
7. Hufnagel TJ, Kim JH, True LD, Manuelidis EE. Immunohistochemistry of capillary hemangioblastoma. Immunoperoxidase-labeled antibody staining resolves the differential diagnosis with metastatic renal cell carcinoma, but does not explain the histogenesis of the capillary hemangioblastoma. Am J Surg Pathol 1989;13:207-216.